Use of four-factor prothrombin complex concentrate for the mitigation of rivaroxaban-induced bleeding in an emergent coronary artery bypass graft

Michael Liu; Cliff Aguele; Umer Darr

doi:10.1002/ccr3.790

Use of four-factor prothrombin complex concentrate for the mitigation of rivaroxaban-induced bleeding in an emergent coronary artery bypass graft

Clin Case Rep. 2017 Mar 28;5(5):636-639. doi: 10.1002/ccr3.790. eCollection 2017 May.

Authors

Michael Liu¹, Cliff Aguele¹, Umer Darr^{1

2}

Affiliations

¹ Yale-New Haven Hospital New Haven Connecticut USA.
² Yale University School of Medicine New Haven Connecticut USA.

Abstract

We presented the first case of four-factor prothrombin complex concentrate (4F-PCC) for the alleviation of bleeding for emergent on-pump coronary artery bypass graft (CABG) with the patient discharged by postoperative day (POD) 9 with no sequelae. Until direct antidotes are available, 4F-PCC may play a role in the management of mitigating rivaroxaban-induced bleeding in surgical procedure.

Keywords: Bleeding; cardiothoracic; coronary artery bypass; four‐factor prothrombin complex concentrate; rivaroxaban.

Publication types

Case Reports